Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy

Jacqueline A. French(Epilepsy Foundation), Mushtaque Chachar, Michael A. Rogawski(University of California, Davis), Michael R. Sperling(Thomas Jefferson University), Robert Wechsler(Family Medicine Residency of Idaho), Jenny Qian(Xenon Pharmaceuticals (Canada)), Shahram Izadyar, Sami Aboumatar, Imran Ali(University of Toledo), George Li, Jerzy P. Szaflarski(University of Alabama at Birmingham), Martin J. Brodie(Western Infirmary), Pavel Klein(Mid Atlantic Epilepsy and Sleep Center), Fawad Khan(Tulane University), Kenneth D. Laxer(California Pacific Medical Center), Evan Fertig, Kamil Detyniecki, Sasha Alick-Lindstrom, Emilio Perucca(The University of Melbourne), David Kudrow(California Medical Clinic for Headache), Toufic Fakhoury, Bassel Abou‐Khalil(Vanderbilt University), Kore Liow(University of Hawaiʻi at Mānoa), Amir Arain, Eric Segal, Gregory N. Beatch(Xenon Pharmaceuticals (Canada)), Dean K. Naritoku, Nathan B. Fountain, Maria Sam, Ernesto Aycardi(Xenon Pharmaceuticals (Canada)), Claude Steriade, Joanne Rogin, Richard Pellegrino(Unknown), Cynthia L. Harden(Xenon Pharmaceuticals (Canada)), Christopher Kenney(Xenon Pharmaceuticals (Canada)), Mercedes Jacobson, Victor Biton(Arkansas Cardiology), Ekrem Kutluay, Constanza Luzon Rosenblut(Xenon Pharmaceuticals (Canada)), Stephanie Callow, Theresa Rodgers-Neame, Ahmad Saeed Ata, Robert Armstrong(Lawrence Livermore National Laboratory), Steve Chung, Simon N. Pimstone(Xenon Pharmaceuticals (Canada)), Stephen Flitman, Elizabeth Waterhouse, Roger J. Porter(University of Pennsylvania), Selim R. Benbadis
JAMA Neurology
October 9, 2023
Cited by 59


Related Papers